Optimizing adjuvant endocrine therapy for postmenopausal breast cancer: the modified CYP2D6 genotype-based modeling analyses

被引：0
|
作者：
Di, G. H. [1 ]
Shao, Z. M. [1 ]
Yu, K. D. [1 ]
机构：
[1] Fudan Univ, Canc Hosp, Shanghai 200433, Peoples R China
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 03期
关键词：
D O I：
10.1016/S1359-6349(10)70445-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：179 / 179
页数：1
相关论文
共 50 条
  • [31] Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial and Re: CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
    Pharoah, Paul D. P.
    Abraham, Jean
    Caldas, Carlos
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (16) : 1263 - 1264
  • [32] Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
    Nakamura, Yusuke
    Ratain, Mark J.
    Cox, Nancy J.
    Mcleod, Howard L.
    Kroetz, Deanna L.
    Flockhart, David A.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (16): : 1264 - 1264
  • [33] Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China
    Lan, Bo
    Ma, Fei
    Chen, Shanshan
    Wang, Wenna
    Li, Qiao
    Fan, Ying
    Luo, Yang
    Cai, Ruigang
    Wang, Jiayu
    Yuan, Peng
    Zhang, Pin
    Li, Qing
    Xu, Binghe
    INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (10) : 2499 - 2504
  • [34] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    Gressier, F.
    Verstuyft, C.
    Hardy, P.
    Becquemont, L.
    Corruble, E.
    JOURNAL OF NEURAL TRANSMISSION, 2015, 122 (01) : 35 - 42
  • [35] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    F. Gressier
    C. Verstuyft
    P. Hardy
    L. Becquemont
    E. Corruble
    Journal of Neural Transmission, 2015, 122 : 35 - 42
  • [36] Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China
    Wei, Xiaoxia
    Sun, Hong
    Zhuang, Jie
    Weng, Xiuhua
    Zheng, Bin
    Lin, Qiwang
    Zhang, Guifeng
    Cai, Jiaqin
    CLINICAL DRUG INVESTIGATION, 2020, 40 (01) : 25 - 32
  • [37] Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China
    Xiaoxia Wei
    Hong Sun
    Jie Zhuang
    Xiuhua Weng
    Bin Zheng
    Qiwang Lin
    Guifeng Zhang
    Jiaqin Cai
    Clinical Drug Investigation, 2020, 40 : 25 - 32
  • [38] Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial Response
    Regan, Meredith M.
    Bouzyk, Mark
    Rae, James M.
    Viale, Giuseppe
    Leyland-Jones, Brian
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (16) : 1266 - 1267
  • [39] FORTY NINE BREAST CANCER PATIENTS WITH THE CYP2D6*4/*4 GENOTYPE
    Dieudonne, A.
    Neven, P.
    Wildiers, H.
    Christiaens, M.
    Weltens, C.
    Vergote, I.
    Lambrechts, D.
    ANNALS OF ONCOLOGY, 2009, 20 : 53 - 53
  • [40] Genotype-based enrichment study design for minimizing the sample size in bioequivalence studies using tolterodine and CYP2D6 genotype
    Oh, Minkyung
    Yeo, Chang-Woo
    Kim, Ho-Sook
    Shon, Jihong
    Shin, Jae-Gook
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2019, 57 (02) : 110 - 116
12345